Make Health Care Work Better For America

IMPROVING QUALITY WHILE CONTAINING COSTS—Health care costs too much in this country, and doesn't deliver enough based on what we pay for it. Fortunately, many of the best ways to improve the quality of our health care would also help contain costs. 

U.S. PIRG is calling on policymakers to go back to the drawing board and start working on solutions that will fix the fundamental problems in the American health care system. 

The bitter and contentious partisan debate in Washington is focused almost entirely on how to contain or assign the extraordinary cost of health insurance. And the specific bills being debated would likely make things worse for millions of Americans by degrading the quality of care, weakening protections for people with pre-existing conditions, and forcing many Americans to give up the coverage they currently have. 

But the biggest failure with these proposals is that they fail to address the underlying problem with the American health care system: We are spending far too much, and getting far too little in return, for our health care dollar. Despite a health care system world-renowned for developing advanced treatments, and an army of skilled and well-meaning doctors, nurses, researchers, hospital and pharmacy staff, our crazy-quilt health care system still fails to deliver an acceptable value proposition for consumers.

Health care is too expensive

Health care costs too much in this country, not because too many people have access to it, but because the system is simply too expensive. From to giant for decades-old medicines like insulin, unjustifiably high costs are everywhere in the U.S. health care system.

And these excessive costs can largely be attributed to widespread waste that doesn’t actually improve quality of care — waste that is to represent a third or more of every dollar we spend on health care. Fortunately, many of the best ways to improve the quality of our health care would also help contain costs.

How we can make health care work better

  • Holding the health care industry to a higher standard. America’s health care system is world-renowned for developing advanced treatments. But we often fail to get the basics right, frequently failing to provide effective, low-cost treatments that work, triggering unnecessary treatments and higher costs down the line. By expanding research into evidence-based medicine and holding providers accountable to higher standards of care, we know we can make progress.
  • Investing in prevention. Our current system rewards hospitals and doctors for performing as many procedures and prescribing as many drugs as possible, with little consideration given toward whether they actually keep us healthy and out of the hospital. We need to change those incentives, and provide easier access to preventative services. Despite some promising small-scale efforts, there’s still far too little being done to change this.
  • Making health care safer for patients. Experts say that medical errors are , yet we do surprisingly little to prevent them. For example, a have been shown to cut hospital-acquired infections in half, yet many hospitals have yet to implement this simple solution, or have .
  • Holding health insurers accountable. There is often too little oversight to ensure insurance companies are delivering on their commitments to their members. In many states, insurers are not held to meaningful standards to ensure adequate access to needed services. Health insurance rate hikes receive little scrutiny even though states that review rates have cut a great deal of waste from premiums—for example, in Oregon, where OSPIRG’s advocacy for consumers has helped cut over from premiums since 2011. By focusing on insurers’ payment strategies and quantitative goals and results, closer scrutiny of health insurers other efforts to drive systemic reforms to improve safety, increase care coordination, boost prevention, and bring down costs for consumers and small businesses.
  • Comprehensive prescription drug reform. America’s prescription drug development and patent system is failing consumers, too often leading to egregious price hikes or the development and marketing of the next “blockbuster” drug that may be of marginal health benefit, rather than research into needed breakthrough therapies for life-threatening conditions. The savings from overhauling the patent system—which gives pharmaceutical corporations immense pricing power—can be reinvested in research into high-priority therapies. Other commonsense reforms could also make a huge difference, like allowing Medicare to negotiate drug prices, requiring drug manufacturers to explain the basis for their prices, and stopping anti-competitive practices by big pharmaceutical corporations.
  • Price transparency for health care services. The very least we can do about rising health care costs is make sure consumers can get prices for services or treatment up front, to allow for more informed decisions about value, encourage price competition that could help keep costs in check, and create accountability for unreasonably high-cost providers.
  • Preserving competition. With countless mergers in recent years between hospital systems, health insurers, pharmaceutical corporations and others, health care has become increasingly consolidated. Unfortunately, bigger is not always better for consumers; studies show consolidation often leads to higher prices and worse service. More scrutiny of health care mergers and tougher anti-trust enforcement against companies that seek to avoid competition could make a big difference.
  • A public option health plan—e.g., providing Americans under 65 with the option of buying into Medicare or Medicaid—could provide consumers with a cheaper alternative to commercial health insurance, ensure that there are coverage options for consumers who lose their employer-based coverage or those in parts of the country where health insurers are dropping coverage, and put pressure on health insurers to provide a better deal or lose our business. 

We need your help

Powerful health care industry lobbyists will fight these changes and work to preserve the status quo, and the politics of health care has never been more divisive. But now is the time—in fact, long past the time—for our leaders to work together to advance the public interest, and address the fundamental problems of cost and quality in our health care system.

Please join us in calling on Congress to take concrete action to make health care work better for American consumers by enacting these commonsense reforms.

Photo credits, clockwise from top: , , .

Issue updates

News Release | U.S. PIRG | Health Care

U.S. PIRG Testifies on “Pay for Delay” Before Senate Subcommittee

Today, Mike Russo, U.S. PIRG's Federal Program Director, testified at a hearing on “Pay-for-Delay Deals: Limiting Competition and Costing Consumers” held by the Senate Judiciary Committee, Subcommittee on Antitrust, Competition and Consumer Rights.

> Keep Reading
News Release | U.S. PIRG | Health Care

Twenty Top Generic Drugs Delayed By Industry Payoffs

Americans with cancer, heart disease, epilepsy and other conditions have been forced to pay an average of 10 times more than necessary for at least 20 blockbuster drugs, according to a report released today by Community Catalyst and U.S. PIRG.

> Keep Reading
Report | U.S. PIRG | Health Care

Top Twenty Pay-For-Delay Drugs

Our research revealed 20 major drugs that were subject to an industry practice called “pay for delay,” in which brand name pharmaceutical companies pay off generic drug manufacturers to keep lower cost equivalents off the market, forcing consumers to pay higher brand-name drug prices.

> Keep Reading
News Release | U.S. PIRG | Health Care

Big Pharma's Pay-for-Delay Deals Take a Hit

Big Pharma's controversial "pay-for-delay" agreements took a hit today. In FTC v. Actavis, the U.S. Supreme Court ruled that the Federal Trade Commission (FTC) case against the payoff keeping generic AndroGel from the market can move ahead in the lower courts. The court chose not to declare all such payoffs unlawful, however, spurring consumer advocates to call on Congress to finish the job. 

> Keep Reading

Senate panel approves tighter oversight of compounding pharmacies but bill is under fire

Public health and consumer advocacy groups are attacking Senate legislation designed to tighten oversight of specialized pharmacies such as the one at the center of this past fall’s deadly meningitis outbreak, saying it does not adequately address health risks.

> Keep Reading

Pages

News Release | U.S. PIRG | Health Care

Supreme Court Upholds Health Reform

Today’s decision is good news for consumers. Insurance companies can’t go back to the days of dropping your coverage once you become ill, or denying coverage to sick children. And beginning in 2014, the days of insurers being able to deny anyone coverage for “pre-existing conditions” will be history. 

> Keep Reading
News Release | U.S. PIRG | Health Care

Senate Approves S.3187 the Food and Drug Administration Safety and Innovation Act S. 3187

The Senate Passage of the Prescription Drug User Fee Act (PDUFA) not Strong Enough to Ensure Sufficient Consumer Safety from Drugs and Medical devices

> Keep Reading
News Release | U.S. PIRG | Health Care

New Health Exchange Rules Help States Move Forward

The rules released today by the federal Department of Health and Human Services put states in the driver’s seat when it comes to setting up new health benefits exchanges.  

> Keep Reading
News Release | U.S. PIRG Education Fund | Health Care

Many states are creating health exchanges to deliver better value for consumers, and other states should follow their lead, according to Making the Grade, a new report by consumer group U.S. PIRG.  Health exchanges are competitive marketplaces that can empower individuals and small businesses with better, more affordable options for coverage.  Under the federal health reform law, each state will have an exchange up and running in 2014. The report closely examines the exchanges that have so far been set up by states and rates them according to how accountable they will be to consumers and the public, how much they can do to lower premiums and improve the quality of care, how friendly they will be to consumers, and how stable they will be.

News Release | U.S. PIRG Education Fund | Health Care

New Health Exchange Rules Put States in the Driver's Seat

The draft rules released today by the federal Department of Health and Human Services put states in the driver’s seat when it comes to setting up new health benefits exchanges.

> Keep Reading

Pages

Report | CALPIRG | Health Care

Playing by Their Own Rules

Drug companies spend billions annually marketing their latest, most expensive drugs to doctors. These marketing efforts do not rely solely on scientific research and medical benefits, however; they employ a barrage of gifts, expensive meals, and wine-and-dine events to gain access to doctors. The result is that doctors looking for objective data about the efficacy and safety of pharmaceuticals are ensnared by this system, and find it increasingly easy to look to the drug companies for information.

> Keep Reading
Report | U.S. PIRG Education Fund | Health Care

Paying the Price 2006

During the spring of 2006, researchers from the state Public Interest Research Groups (PIRGs) posed as uninsured customers and surveyed by phone hundreds of pharmacies in 35 cities across the country to determine how much uninsured consumers are paying for 10 prescription drugs commonly used by adults under age 65. We then compared these prices with the prices the pharmaceutical companies charge the federal government; with prices at a Canadian pharmacy; and with the results of a similar survey we completed in 2004.

> Keep Reading
Report | U.S. PIRG | Health Care

Turning Medicine Into Snake Oil

Prescription drug marketers are inundating doctors, and to a lesser extent, the public, with marketing that misrepresents risks, promotes unproven uses, and makes unsubstantiated claims. The false and misleading messages are communicated through conventional advertising, sales representatives, doctors speaking on behalf of drug marketers, and through clinical trial suppression, manipulation and misrepresentation. Sadly, the Food and Drug Administration (FDA) is ineffective at addressing the problems.

> Keep Reading
Report | U.S. PIRG | Health Care

Paying the Price 2004

In late summer of 2004, the PIRGs conducted a survey of more than 400 pharmacies in 19 states across the country and Washington, DC to determine how much uninsured consumers are paying for 12 prescription drugs commonly used by adults under age 65. We then compared these prices with the prices the pharmaceutical companies charge one of their “most favored” customers, the federal government, and also with the prices paid by consumers in Canada.

> Keep Reading
Report | U.S. PIRG Education Fund | Health Care

Paying the Price 2003

In the spring of 2003, the National Association of State Public Interest Research Groups (PIRGs) conducted a survey of more than 500 pharmacies in 18 states across the country and Washington, D.C. to determine how much uninsured consumers are paying for 10 common prescription drugs. We then compared these prices with the prices the pharmaceutical companies charge one of their “most favored” customers, the federal government.

> Keep Reading

Pages

View AllRSS Feed

Support Us

Your donation supports U.S. PIRG’s work to stand up for consumers on the issues that matter, especially when powerful interests are blocking progress.

Consumer Alerts

Join our network and stay up to date on our campaigns, get important consumer updates and take action on critical issues.
Optional Member Code
https://velotime.com.ua

best-cooler.reviews

maxformer.com/telezhki-gidravlicheskie